Experimental findings show ISR influences microglial response and cytokine release, highlighting therapeutic potential.
Abstract Microglia undergo a dynamic pro-inflammatory phenotypic shift in response to acute injury and disease. However, inappropriate microglia reactivity impairs homeostatic resolution and exacerbates neurodegeneration. The integrated stress response (ISR) is a putative signalling pathway that mediates both intrinsic and extracellular stress. Thus, the ISR is an attractive target for investigation as a novel modulator of microglia reactivity. In the present study, ISR activation is stimulated through toxin-mediated perturbations to proteostasis, validating the efficacy of pharmacological ISR inhibition in primary microglia in vitro. This study demonstrates that ISR-dependent, non-canonical priming and inflammasome activation are sufficient to induce the release of pro-inflammatory cytokines and paracrine stimulation of naïve microglia. Furthermore, ISR inhibition rescues survival, homeostatic morphology, and upregulation of phagocytic activity. These results suggest that the ISR is a novel effector of microglial activation. Therapeutic ISR manipulation may be a tangible target for mediating microglia behaviour, restoring brain homeostasis, and mitigating the deleterious effects of sustained neuroinflammation.
No takes yet. Share an insight, caveat, or question.
Kane et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: